IIVS | Integrated Testing Strategies for Skin Sensitization
page-template-default,page,page-id-609,page-child,parent-pageid-540,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-,vc_responsive

Integrated Testing Strategies for Skin Sensitization

Determination of skin sensitization potential is a critical endpoint in the safety assessment of raw materials, chemicals, mixtures and formulations. Although the Guinea Pig Maximization Test (GPMT) and Local Lymph node assay (LLNA) have historically been used to address this adverse effect, in vitro assays have been developed and validated in order to replace these resource-intensive animal tests.

Since skin sensitization is the result of a cascade of Key Events (KEs) involving hapten (generally a low-molecular weight compound) binding, upregulation of cellular proteins and immune cell activation, it is generally agreed by the toxicology community that an Integrated Testing Strategy that combines multiple assays is needed to fully replace the animal based methods.

In order to fully support our clients’ needs, IIVS offers a suite of in vitro assays and testing strategies designed to address all three KEs in the Adverse Outcome Pathway. Additionally, studies can be performed under Good Laboratory Practices in order to generate submission-grade reports.

Please contact us for further information on our capabilities and how they may be used as part of an integrated testing strategy within your existing testing program.